Kymera IPO Presentation Deck
August 2020, 49 slides
  1. Kymera
  2. Related Decks
  3. IPO Presentation Decks
inventing new medicines | Kymera
legal disclaimer | Kymera
offering summary | Kymera
investment highlights | Kymera
leadership team a | Kymera
financial highlights a yale | Kymera
strategic collaborations a | Kymera
targeted protein degradation | Kymera
targeted protein degradation | Kymera
| Kymera
proprietary platform | Kymera
| Kymera
chat | Kymera
| Kymera
| Kymera
drug development principles oii and | Kymera
robust pipeline of targeted protein degraders for drugged targets | Kymera
| Kymera
biology and degrader rationale me | Kymera
specific degradation | Kymera
degradation superior to kinase inhibition in production | Kymera
degradation superior to kinase inhibition in intracellular signaling | Kymera
degradation active in preclinical mouse psoriasis model | Kymera
degradation active in preclinical mouse gout model | Kymera
close to complete degradation and well tolerated in preclinical non rodent model | Kymera
development plan | Kymera
| Kymera
wis pane | Kymera
degradation of and correlates to cell killing esses | Kymera
superior to inhibition and single agents | Kymera
tumor regressions from substantial degradation of and substrates in preclinical model a | Kymera
lead selective for tumors irrespective of mutations | Kymera
tumor regressions from intermittent dosing in preclinical model | Kymera
development in mutant | Kymera
i | Kymera
biology and degrader rationale | Kymera
disease impact in oncology autoimmunity | Kymera
highly specific degradation of | Kymera
degradation and downstream effects across tumor cells i | Kymera
full and durable regressions across multiple | Kymera
degradation as resistant mechanism in solid tumors | Kymera
degradation in tumor | Kymera
degrader active in preclinical refractory | Kymera
degrader active in cell activation preclinical in model mang | Kymera
degrader clinical development plan in liquid and solid tumors | Kymera
| Kymera
upcoming catalysts | Kymera
investment highlights | Kymera
thank you | Kymera
See More
Kymera
IPO Presentation Decks
Biotechnology Decks
Healthcare Decks
Explore Topics
Tumor
Preclinical
Oncology
Solid tumor
Recent decks by Kymera
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
See all presentations by Kymera (7 decks)
Related decks
Nuvalent
Investor Presentation
October 2022
Nuvalent
Investor Presentation
August 2023
Alkermes
Investor Presentation
October 2023
TScan Therapeutics
IPO
July 2021
Nuvectis Pharma
Investor Presentation
December 2023
Nuvalent
Investor Presentation
November 2023
BioNTech
Results
August 2022
Nuvectis Pharma
Investor Presentation
July 2023
Recent decks by Kymera
See all presentations (7 decks)
Investor Presentation
December 2023
Investor Presentation
November 2023
Investor Presentation
August 2023
Investor Presentation
June 2023
Nuvalent
Investor Presentation
October 2022
Nuvalent
Investor Presentation
August 2023
Alkermes
Investor Presentation
October 2023
TScan Therapeutics
IPO
July 2021
Nuvectis Pharma
Investor Presentation
December 2023
Nuvalent
Investor Presentation
November 2023
BioNTech
Results
August 2022
Nuvectis Pharma
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights